Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections
- Urothelial - Phase 2 data for investigational urothelial cancer therapy, erdafitinib- Hematologic - IMBRUVICA® Phase 3 data in first-line and relapsed/refractory Waldenström's macroglobulinemia;...
Page (1) of 1 - 05/16/18||
This article is no longer available,but here are some related topics.
All Rights Reserved